Lenalidomide

ʻO ka wehewehe pōkole:

Ka inoa o ka API Hōʻike Hōʻike US DMF EU DMF CEP
Lenalidomide Laʻau oncology I-Hale 31804  


Huahana Huahana

Huahana Huahana

NUI HUA

wehewehe

ʻO Lenalidomide (CC-5013) kahi huaʻōlelo o Thalidomide a me kahi immunomodulator hoʻoikaika waha.ʻO Lenalidomide (CC-5013) kahi ligand o ka ubiquitin E3 ligase cereblon (CRBN), a ke kumu ia i ka ubiquitination koho a me ka hoʻohaʻahaʻa ʻana o nā mea transcription lymphoid ʻelua, IKZF1 a me IKZF3, e ka CRBN-CRL4 ubiquitin ligase.ʻO Lenalidomide (CC-5013) kaohi pono i ka ulu ʻana o nā lymphomas B-cell makua, me ka myeloma lehulehu, a hoʻoulu i ka hoʻokuʻu ʻana o IL-2 mai nā pūnaewele T.

Ka hope

ʻO Lenalidomide (ʻike pū ʻia ʻo CC-5013), he ʻano oral derivative o thalidomide, he antineoplastic agent e hōʻike ana i ka hana antitumor ma o nā ʻano hana like ʻole, me ka hoʻoulu ʻana o ka ʻōnaehana pale, ka inhibition angiogenesis, a me nā hopena antineoplastic pololei.Ua aʻo nui ʻia no ka mālama ʻana i ka myeloma lehulehu a me ka myelodysplastic syndrome a me nā maʻi lymphoproliferative e pili ana i ka maʻi lymphocytic leukemia (CLL) a me ka lymphoma non-Hodgkin.Wahi a nā noiʻi hou loa, hoʻolalelale ʻo Lnalidomide a hoʻihoʻi i ka hana ʻōnaehana immune i nā maʻi CLL ma o ka hoʻoulu ʻana i ka overexpression o nā molekala costimulatory i loko o nā lymphocytes leukemic e hoʻihoʻi i ka hoʻomaʻamaʻa humoral a me ka hana immunoglobulins a me ka hoʻomaikaʻi ʻana i ka hiki o nā cell T a me nā cell leukemic e hana i nā synapses me T lymphocytes.

Kuhikuhi

Ana Pilar Gonzalez-Rodriguez, Angel R. Payer, Andrea Acebes-Huerta, Leticia Hergo-Zapico, Monica Villa-Alvarez, Esther Gonzalez-Garcia, and Segundo Gonzalez.Lenalidomide a me ka leukemia lymphocytic mau loa.BioMed Research International 2013.

In Vitro

He ikaika ka Lenalidomide i ka hoʻoulu ʻana i ka hoʻonui ʻana o ka cell T a me IFN-γ a me ka hana IL-2.Ua hōʻike ʻia ʻo Lenalidomide e kāohi i ka hana ʻana o nā cytokine pro inflammatory TNF-α, IL-1, IL-6, IL-12 a hoʻokiʻekiʻe i ka hana o anti-inflammatory cytokine IL-10 mai nā PBMC kanaka.Hoʻohaʻahaʻa ʻo Lenalidomide i ka hana ʻana o ka IL-6 pololei a me ka hoʻopaʻa ʻana i nā pūnaewele myeloma (MM) a me ka launa pū ʻana o ka iwi marrow stromal cell (BMSC), e hoʻonui ana i ka apoptosis o nā cell myeloma [2].ʻIke ʻia ka launa pū ʻana me ka CRBN-DDB1 complex me Thalidomide, Lenalidomide a me Pomalidomide, me nā waiwai IC50 o ~30μM, ~3μM a me ~3μM, kēlā me kēia, ʻO kēia mau pūnaewele hōʻike CRBN i hōʻemi ʻia (U266-CRBN60 a me U266-CRBN75) ʻoi aku ka liʻiliʻi o ka pane ʻana ma mua o nā cell makua i nā hopena antiproliferative Lenalidomide ma waena o kahi pae pane-pane o 0.01 a 10.μM[3].ʻO Lenalidomide, kahi analog thalidomide, hana ma ke ʻano he molecular glue ma waena o ke kanaka E3 ubiquitin ligase cereblon a me CKIα hōʻike ʻia e hoʻoulu i ka ubiquitination a me ka hoʻohaʻahaʻa ʻana o kēia kinase, no laila ke pepehi ʻia nei nā cell leukemic e ka p53 activation.

ʻO ka ʻawaʻawa o Lenalidomide a hiki i ka 15, 22.5, a me 45 mg/kg ma o nā ala IV, IP, a me PO o ka hoʻokele.Hoʻopaʻa ʻia e ka solubility i loko o kā mākou PBS dosing kaʻa, ʻae maikaʻi ʻia kēia mau kikoʻī Lenalidomide kiʻekiʻe loa me ka ʻokoʻa o hoʻokahi make ʻiole (o ʻehā mau dosed) ma ka 15 mg/kg IV.ʻO ka mea nui, ʻaʻohe mea ʻona ʻē aʻe i ʻike ʻia ma ke aʻo ʻana ma nā kaila IV o 15 mg/kg (n=3) a i ʻole 10 mg/kg (n=45) a i ʻole ma kekahi pae pae ma o nā ala IV, IP, a me PO.

Waihona

Pauda

-20°C

3 makahiki
 

4°C

2 makahiki
I ka solvent

-80°C

6 mahina
 

-20°C

1 mahina

ʻO ke kinona

Lenalidomide

ʻIkepili olaola pili

Related Biological Data

ʻIkepili olaola pili

Related Biological Data2

HOOLAHA ANOAI

Quality management1

Manaʻo18Nā papahana Loiloi Kūlike Kūlike i ʻae ʻia4, a6nā papahana ma lalo o ka ʻae ʻia.

Quality management2

Ua hoʻokumu ka ʻōnaehana hoʻokele maikaʻi honua kiʻekiʻe i ke kumu kūʻai.

Quality management3

Holo ka nānā ʻana i ka maikaʻi ma ke ola holoʻokoʻa o ka huahana e hōʻoia i ka maikaʻi a me ka hopena therapeutic.

Quality management4

Kākoʻo ka hui ʻoihana Regulatory Affairs i nā koi maikaʻi i ka wā o ke noi a me ke kau inoa ʻana.

HOOLAHA HANA

cpf5
cpf6

Kolea Countec Bottled Packaging Line

cpf7
cpf8

ʻO Taiwan CVC Bottled Packaging Line

cpf9
cpf10

ʻO Italia CAM Board Packaging Line

cpf11

Mekini Fette Compacting German

cpf12

ʻO Iapana Viswill Tablet ʻIke

cpf14-1

Keena Mana DCS

HOA

Ka launa pū ʻana o ka honua
International cooperation
ʻO ka launa pū ʻana o ka hale
Domestic cooperation

  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou